Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Non-Small Cell Lung Cancer

In brief

The combination of oxaliplatin and gemcitabine has proven activity in advanced non-small cell lung cancer (NSCLC). Due to its favorable toxicity profile, this combination is optimal for adding new agents. Bevacizumab is an anti-VEGF monoclonal antibody that has also shown favorable results in advanced NSCLC. This study will add bevacizumab to oxaliplatin and gemcitabine as first line treatment in patients with Stage IIIB and IV NSCLC.

Key facts

Study ID

NCT00217282

Run by

Mt. Sinai Medical Center, Miami

People needed

45

Starts

2004-06-01

Expected to finish

2008-03-01

Last updated by the study team

2008-05-22

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed non-small cell lung cancer, EXCEPT squamous cell cancer
• Stage IIIB or IV disease
• ECOG PS 0-1
• No prior treatment
• No brain metastases
• Must have measurable disease

You may not qualify if…

• Deep vein thromboses or pulmonary embolus within 1 year
• History of gross hemoptysis

Where it is running

• Mount Sinai Medical Center — Miami Beach, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.